Back
Rate this talk
Your peers have not rated this talk yet.
4-minute watch | Talk 1 of 1

ASH 2024

Predictors of survival after 1L therapy in DLBCL

Prof. Ran Reshef
PERSPECTIVE
ASH

Prof. Ran Reshef discusses Predictors of survival after 1L therapy in DLBCL

Read more

Talks in this series

Dr Caroline Lee discusses CIBMTR: RWE CAR T in 2L R/R DLBCL
3-minute watch | Talk of
CIBMTR: RWE CAR T in 2L R/R DLBCL
Dr Caroline Lee
Dr Caroline Lee discusses CIBMTR: RWE CAR T in 2L R/R DLBCL
3-minute watch

CIBMTR: RWE CAR T in 2L R/R DLBCL

Dr Caroline Lee

 Prof. Marcello Pasquini analyses the evolution of safety management and a reduction in acute toxicities with axi-cel
2-minute watch | Talk of
Evolution of safety management and a reduction in acute toxicities with axi-cel
Prof. Marcello Pasquini
 Prof. Marcello Pasquini analyses the evolution of safety management and a reduction in acute toxicities with axi-cel
2-minute watch

Evolution of safety management and a reduction in acute toxicities with axi-cel

Prof. Marcello Pasquini

 Dr Lori Leslie presents Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
5-minute watch | Talk of
Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
Dr Lori Leslie
 Dr Lori Leslie presents Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
5-minute watch

Outpatient administration of axi-cel: updates from ZUMA-24 and RWE

Dr Lori Leslie

 Dr Lori Muffly discusses Brexu-cel in R/R aALL: UK RWE
3-minute watch | Talk of
Brexu-cel in R/R aALL: UK RWE
Dr Lori Muffly
 Dr Lori Muffly discusses Brexu-cel in R/R aALL: UK RWE
3-minute watch

Brexu-cel in R/R aALL: UK RWE

Dr Lori Muffly

 Dr Lori Muffly discusses Brexu-cel in R/R aALL: US RWE
9-minute watch | Talk of
Brexu-cel in R/R aALL: US RWE
Dr Lori Muffly
 Dr Lori Muffly discusses Brexu-cel in R/R aALL: US RWE
9-minute watch

Brexu-cel in R/R aALL: US RWE

Dr Lori Muffly

Dr Fred Locke explores Who should be referred for CAR T?
2-minute watch | Talk of
Who should be referred for CAR T?
Dr Fred Locke
Dr Fred Locke explores Who should be referred for CAR T?
2-minute watch

Who should be referred for CAR T?

Dr Fred Locke

Dr Fred Locke discusses Curative potential with axi-cel in R/R DLBCL
2-minute watch | Talk of
Curative potential with axi-cel in R/R DLBCL
Dr Fred Locke
Dr Fred Locke discusses Curative potential with axi-cel in R/R DLBCL
2-minute watch

Curative potential with axi-cel in R/R DLBCL

Dr Fred Locke

Dr Pierre Sesques provides Updates from DESCAR-T
4-minute watch | Talk 1 of 1
ASH 2024
Updates from DESCAR-T
Dr Pierre Sesques provides Updates from DESCAR-T
4-minute watch
ASH 2024

Updates from DESCAR-T

Dr Pierre Sesques presents ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
3-minute watch | Talk 1 of 1
ASH 2024
ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
Dr Pierre Sesques presents ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
3-minute watch
ASH 2024

ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients

 Dr Gloria Iacoboni of Valdebron University Hospital in Barcelona, Spain provides her perspective on the five-year update in ZUMA-2
2-minute watch | Talk 1 of 1
ASH 2024
ZUMA-2: Brexu-cel in R/R MCL five year update
 Dr Gloria Iacoboni of Valdebron University Hospital in Barcelona, Spain provides her perspective on the five-year update in ZUMA-2
2-minute watch
ASH 2024

ZUMA-2: Brexu-cel in R/R MCL five year update

 Dr Kai Rejeski discusses NRM post CAR T: what do we need to know?
5-minute watch | Talk 1 of 1
ASH 2024
NRM post CAR T: what do we need to know?
 Dr Kai Rejeski discusses NRM post CAR T: what do we need to know?
5-minute watch
ASH 2024

NRM post CAR T: what do we need to know?

 Dr Kai Rejeski presents CAR-Tography: getting a better understanding of acute toxicities post-CAR T
5-minute watch | Talk 1 of 1
ASH 2024
CAR-Tography: getting a better understanding of acute toxicities post-CAR T
 Dr Kai Rejeski presents CAR-Tography: getting a better understanding of acute toxicities post-CAR T
5-minute watch
ASH 2024

CAR-Tography: getting a better understanding of acute toxicities post-CAR T

 Prof. Ran Reshef discusses Predictors of survival after 1L therapy in DLBCL
4-minute watch | Talk 1 of 1
ASH 2024
Predictors of survival after 1L therapy in DLBCL
 Prof. Ran Reshef discusses Predictors of survival after 1L therapy in DLBCL
4-minute watch
ASH 2024

Predictors of survival after 1L therapy in DLBCL

 Prof. Ran Reshef discusses CAR T vs BsAbs: which one to use first?
2-minute watch | Talk 1 of 1
ASH 2024
CAR T vs BsAbs: which one to use first?
 Prof. Ran Reshef discusses CAR T vs BsAbs: which one to use first?
2-minute watch
ASH 2024

CAR T vs BsAbs: which one to use first?

 Prof. Ran Reshef analyses can interim PET aid early identification of patients for CAR T?
4-minute watch | Talk 1 of 1
ASH 2024
Can interim PET aid early identification of patients for CAR T?
 Prof. Ran Reshef analyses can interim PET aid early identification of patients for CAR T?
4-minute watch
ASH 2024

Can interim PET aid early identification of patients for CAR T?

 Dr Marcela Maus analyses what approaches are being used to prevent and mitigate CAR T toxicities?
3-minute watch | Talk 1 of 1
ASH 2024
What approaches are being used to prevent and mitigate CAR T toxicities?
 Dr Marcela Maus analyses what approaches are being used to prevent and mitigate CAR T toxicities?
3-minute watch
ASH 2024

What approaches are being used to prevent and mitigate CAR T toxicities?

Dr Gloria Iacoboni of Valdebron University Hospital in Barcelona, Spain discusses how is MCL managed with CAR T? Results from the EBMT survey
5-minute watch | Talk 1 of 1
ASH 2024
How is MCL managed with CAR T? Results from the EBMT survey
Dr Gloria Iacoboni of Valdebron University Hospital in Barcelona, Spain discusses how is MCL managed with CAR T? Results from the EBMT survey
5-minute watch
ASH 2024

How is MCL managed with CAR T? Results from the EBMT survey

Dr Caroline Lee discusses CIBMTR: RWE CAR T in 2L R/R DLBCL
3-minute watch | Talk of
CIBMTR: RWE CAR T in 2L R/R DLBCL
Dr Caroline Lee
Dr Caroline Lee discusses CIBMTR: RWE CAR T in 2L R/R DLBCL
3-minute watch

CIBMTR: RWE CAR T in 2L R/R DLBCL

Dr Caroline Lee

 Prof. Marcello Pasquini analyses the evolution of safety management and a reduction in acute toxicities with axi-cel
2-minute watch | Talk of
Evolution of safety management and a reduction in acute toxicities with axi-cel
Prof. Marcello Pasquini
 Prof. Marcello Pasquini analyses the evolution of safety management and a reduction in acute toxicities with axi-cel
2-minute watch

Evolution of safety management and a reduction in acute toxicities with axi-cel

Prof. Marcello Pasquini

 Dr Lori Leslie presents Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
5-minute watch | Talk of
Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
Dr Lori Leslie
 Dr Lori Leslie presents Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
5-minute watch

Outpatient administration of axi-cel: updates from ZUMA-24 and RWE

Dr Lori Leslie

 Dr Lori Muffly discusses Brexu-cel in R/R aALL: UK RWE
3-minute watch | Talk of
Brexu-cel in R/R aALL: UK RWE
Dr Lori Muffly
 Dr Lori Muffly discusses Brexu-cel in R/R aALL: UK RWE
3-minute watch

Brexu-cel in R/R aALL: UK RWE

Dr Lori Muffly

 Dr Lori Muffly discusses Brexu-cel in R/R aALL: US RWE
9-minute watch | Talk of
Brexu-cel in R/R aALL: US RWE
Dr Lori Muffly
 Dr Lori Muffly discusses Brexu-cel in R/R aALL: US RWE
9-minute watch

Brexu-cel in R/R aALL: US RWE

Dr Lori Muffly

Dr Fred Locke explores Who should be referred for CAR T?
2-minute watch | Talk of
Who should be referred for CAR T?
Dr Fred Locke
Dr Fred Locke explores Who should be referred for CAR T?
2-minute watch

Who should be referred for CAR T?

Dr Fred Locke

Dr Fred Locke discusses Curative potential with axi-cel in R/R DLBCL
2-minute watch | Talk of
Curative potential with axi-cel in R/R DLBCL
Dr Fred Locke
Dr Fred Locke discusses Curative potential with axi-cel in R/R DLBCL
2-minute watch

Curative potential with axi-cel in R/R DLBCL

Dr Fred Locke

Dr Pierre Sesques provides Updates from DESCAR-T
4-minute watch | Talk 1 of 1
ASH 2024
Updates from DESCAR-T
Dr Pierre Sesques provides Updates from DESCAR-T
4-minute watch
ASH 2024

Updates from DESCAR-T

Dr Pierre Sesques presents ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
3-minute watch | Talk 1 of 1
ASH 2024
ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
Dr Pierre Sesques presents ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
3-minute watch
ASH 2024

ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients

 Dr Gloria Iacoboni of Valdebron University Hospital in Barcelona, Spain provides her perspective on the five-year update in ZUMA-2
2-minute watch | Talk 1 of 1
ASH 2024
ZUMA-2: Brexu-cel in R/R MCL five year update
 Dr Gloria Iacoboni of Valdebron University Hospital in Barcelona, Spain provides her perspective on the five-year update in ZUMA-2
2-minute watch
ASH 2024

ZUMA-2: Brexu-cel in R/R MCL five year update

 Dr Kai Rejeski discusses NRM post CAR T: what do we need to know?
5-minute watch | Talk 1 of 1
ASH 2024
NRM post CAR T: what do we need to know?
 Dr Kai Rejeski discusses NRM post CAR T: what do we need to know?
5-minute watch
ASH 2024

NRM post CAR T: what do we need to know?

 Dr Kai Rejeski presents CAR-Tography: getting a better understanding of acute toxicities post-CAR T
5-minute watch | Talk 1 of 1
ASH 2024
CAR-Tography: getting a better understanding of acute toxicities post-CAR T
 Dr Kai Rejeski presents CAR-Tography: getting a better understanding of acute toxicities post-CAR T
5-minute watch
ASH 2024

CAR-Tography: getting a better understanding of acute toxicities post-CAR T

 Prof. Ran Reshef discusses Predictors of survival after 1L therapy in DLBCL
4-minute watch | Talk 1 of 1
ASH 2024
Predictors of survival after 1L therapy in DLBCL
 Prof. Ran Reshef discusses Predictors of survival after 1L therapy in DLBCL
4-minute watch
ASH 2024

Predictors of survival after 1L therapy in DLBCL

 Prof. Ran Reshef discusses CAR T vs BsAbs: which one to use first?
2-minute watch | Talk 1 of 1
ASH 2024
CAR T vs BsAbs: which one to use first?
 Prof. Ran Reshef discusses CAR T vs BsAbs: which one to use first?
2-minute watch
ASH 2024

CAR T vs BsAbs: which one to use first?

 Prof. Ran Reshef analyses can interim PET aid early identification of patients for CAR T?
4-minute watch | Talk 1 of 1
ASH 2024
Can interim PET aid early identification of patients for CAR T?
 Prof. Ran Reshef analyses can interim PET aid early identification of patients for CAR T?
4-minute watch
ASH 2024

Can interim PET aid early identification of patients for CAR T?

 Dr Marcela Maus analyses what approaches are being used to prevent and mitigate CAR T toxicities?
3-minute watch | Talk 1 of 1
ASH 2024
What approaches are being used to prevent and mitigate CAR T toxicities?
 Dr Marcela Maus analyses what approaches are being used to prevent and mitigate CAR T toxicities?
3-minute watch
ASH 2024

What approaches are being used to prevent and mitigate CAR T toxicities?

Dr Gloria Iacoboni of Valdebron University Hospital in Barcelona, Spain discusses how is MCL managed with CAR T? Results from the EBMT survey
5-minute watch | Talk 1 of 1
ASH 2024
How is MCL managed with CAR T? Results from the EBMT survey
Dr Gloria Iacoboni of Valdebron University Hospital in Barcelona, Spain discusses how is MCL managed with CAR T? Results from the EBMT survey
5-minute watch
ASH 2024

How is MCL managed with CAR T? Results from the EBMT survey

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

  This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.